Crestor®
Rosuvastatin is a high-potency HMG-CoA reductase inhibitor (statin) for lowering LDL cholesterol and reducing cardiovascular risk.
| Dosage Form | Oral Tablet |
| Strength | 5 mg, 10 mg, 20 mg, 40 mg |
| Storage | Store at 20–25°C. Protect from moisture. |
| Category | Cardiovascular |
| Availability | Available for Transfer |
Hyperlipidemia; mixed dyslipidemia; hypertriglyceridemia; primary prevention of cardiovascular events; slowing progression of atherosclerosis.
Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis, upregulating LDL receptor expression and increasing LDL-C clearance.
Each Burrard Pharmaceuticals technology transfer package for Rosuvastatin includes comprehensive documentation and support:
Complete formulation with manufacturing parameters, excipient specifications, and process controls.
Validated methods for assay, impurities, dissolution, and stability-indicating analysis.
Market-ready regulatory dossier templates — available through Burrard Intelligence subscription.
ICH-compliant stability studies (accelerated and long-term) with detailed protocols.
Scale-up procedures, batch records, equipment specifications, and in-process controls.
Direct advisory access to formulation scientists and regulatory specialists throughout transfer.
Our team can deliver the complete know-how package within 2–21 business days. Book a consultation to discuss your specific requirements.